CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Liposomal Drug Product Development and Quality: Current US Experience and Perspective

Kapoor, Mamta, Lee, Sau L., Tyner, Katherine M. · 2017 · The AAPS Journal

Abstract

Research in the area of liposomes has grown substantially in the past few decades. Liposomes are lipid bilayer structures that can incorporate drug substances to modify the drug's pharmacokinetic profile thereby improving drug delivery. The agency has received over 400 liposomal drug product submissions (excluding combination therapies), and there are currently eight approved liposomal drug products on the US market. In order to identify the pain points in development and manufacturing of liposomal drug products, a retrospective analysis was performed from a quality perspective on submissions for new and generic liposomal drug products. General analysis on liposomal drug product submissions was also performed. Results indicated that 96% of the submissions were Investigational New Drug (IND) applications, 3% were New Drug Applications (NDAs), and the remaining 1% was Abbreviated New Drug Applications (ANDAs). Doxorubicin hydrochloride was the most commonly used drug substance incorporated into the liposomes (31%). The majority of the liposomal products were administered via intravenous route (84%) with cancer (various types) being the most common indication (63%). From a quality perspective, major challenges during the development of liposomal drug products included identification and (appropriate) characterization of critical quality attributes of liposomal drug products and suitable control strategies during product development. By focusing on these areas, a faster and more…

Overview

Integrity signals

Registry

Crossref · 10.1208/s12248-017-0049-9

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 8

  1. Pharmaceutical Development Q8(R2). International Conference on Harmonisation. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf . (2009). Accessed 04 Jun 2016.
  2. Srinivasan A, Iser R. FDA perspectives: common deficiencies in Abbreviated New Drug Applications: part 1: drug substance. Pharm Technol. 2010;34(1):50–9.
  3. Srinivasan A, Iser R. FDA perspectives: common deficiences in Abbreviated New Drug Applications (part 4). Pharm Technol. 2011;35(4):62–8.
  4. Srinivasan A, Iser R, Gill DS. FDA perspectives: common deficiencies in Abbreviated New Drug Applications: part 2: description, composition, and excipients. Pharm Technol. 2010;34(8):45–51.
  5. Srinivasan A, Iser R, Gill DS. FDA perspectives: common deficiencies in Abbreviated New Drug Applications: part 3-control of the drug product and stability. Pharm Technol. 2011;35(2):58–67.
  6. Impurities in New Drug Products Q3B (R2). International Conference on Harmonisation. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdf . (2006). Accessed 04 Jan 2017.
  7. Pharmaceutical Quality System Q10. International Conference on Harmonisation. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf . (2008). Accessed 14 Jun 2016.
  8. Quality Risk Management Q9. International Conference on Harmonisation. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf . (2005). Accessed 10 Aug 2016.

Cited by

See all 116

Metadata

Authors
Kapoor, M., Lee, S. L., & Tyner, K. M.
Affiliations
United States Food and Drug Administration (US)
Corresponding author
Tyner, Katherine M.
Venue
The AAPS Journal
Published
2017-02-03
Volume
19
Issue
3
Pages
632-641
ISSN
1550-7416 (ISSN-L)
OpenAlex
W2584301648
Cited by
116
References
32
Citations by year
2026: 9 · 2025: 19 · 2024: 19 · 2023: 9 · 2022: 12 · 2021: 11 · 2020: 16 · 2019: 11 · 2018: 5 · 2017: 5
FWCI
3.63
Type
journal article
Language
en
Open access
closed
Locations
  • The AAPS Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
pharmaceutical product development, drug quality, critical quality attributes, pharmaceutical manufacturing, regulatory submissions, Investigational New Drug application, new drug applications, abbreviated new drug application, doxorubicin hydrochloride, intravenous administration
MeSH terms
Drug Carriers, Drug Industry, Liposomes, Quality Control, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liposomal Drug Product Development and Quality: Current US Experience and Perspective. https://app.cochat.ai/papers/10.1208/s12248-017-0049-9
The paper
Kapoor, M., Lee, S. L., & Tyner, K. M. (2017). Liposomal Drug Product Development and Quality: Current US Experience and Perspective. The AAPS Journal. https://doi.org/10.1208/s12248-017-0049-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.